Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?

Area of Science:

• Hepatology
• Molecular Biology
• Metabolic Diseases

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a global health concern, progressing from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, and liver cancer.
• Hepatic lipotoxicity, driven by excessive fatty acid influx overwhelming hepatocyte processing capacity, is central to NAFLD progression.
• Key molecular mechanisms include endoplasmic reticulum stress, oxidative stress, impaired autophagy, lipoapoptosis, and inflammation.

Purpose of the Study:

• To review the molecular mechanisms underlying hepatic lipotoxicity in NAFLD.
• To elucidate the specific role of CD36/FAT fatty acid translocase in NAFLD pathogenesis.
• To explore therapeutic strategies targeting CD36 for NAFLD treatment.

Main Methods:

• Literature review of molecular mechanisms in NAFLD.
• Analysis of studies on fatty acid translocase CD36 in liver disease.
• Examination of clinical data on CD36 expression and NAFLD severity.

Main Results:

• CD36 facilitates fatty acid uptake, promoting hepatosteatosis and potentially NASH progression.
• Increased CD36 expression is observed in the livers of NAFLD patients.
• Elevated circulating soluble CD36 (sCD36) levels correlate with NAFLD severity.

Conclusions:

• CD36 translocation to the hepatocyte membrane is a critical factor in NAFLD pathophysiology.
• Targeting CD36 or its regulators presents a promising therapeutic avenue for NAFLD prevention and treatment.